ASCO GI 2027: 5 GI Cancer Abstracts That Could Move Stocks

Every biotech investor knows ASCO moves stocks. Fewer screen the ASCO Gastrointestinal Cancers Symposium systematically, and that is the edge. ASCO GI 2027 runs January 21 through 23 in San Francisco, and it is the first major oncology catalyst window of the year. The trade fires before anyone steps on a podium. Abstract titles drop December 15, 2026, and full abstracts release January 19, 2027 at 5:00 pm ET, roughly two days before the first session. By the time a presenter walks up, the stocks that matter have already gapped. That is the calendar you are trading against.

GI oncology is the sector’s quiet monster. Pancreatic, gastric, and colorectal cancers collectively kill more Americans than breast or prostate cancer, and 2026 turned KRAS, CLDN18.2, and PD-1/VEGF bispecifics into the three hottest GI programs in a decade. The playbook is unchanged from the ESMO 2026 biotech abstracts preview: screen the mid- and small-caps where one dataset re-rates a stock 15 to 30 percent, ignore the mega-caps whose GI data moves zero basis points, and know which catalysts have already been consumed before abstract day.

1. Revolution Medicines (RVMD), $201.74, $43.24 billion cap. The name to screen first. Daraxonrasib, now branded Rasonque, won FDA approval in August as the first RAS inhibitor for pancreatic cancer, nearly doubling median overall survival to 13.2 months in second-line disease. That catalyst is consumed and priced. What is not priced is the first-line expansion, which is where the franchise doubles or triples. Revolution is running three Phase 3s in untreated metastatic pancreatic cancer: RASolute 303 testing daraxonrasib plus or minus chemo against gemcitabine and nab-paclitaxel, RASolute 305 testing the G12D-selective zoldonrasib plus chemo against placebo plus chemo, and a planned zoldonrasib-plus-daraxonrasib doublet. The screen is updated zoldonrasib first-line data and any RASolute 303 enrollment or early signal. At ESMO GI 2026, zoldonrasib (RVMD) plus mFOLFIRINOX posted an 82% objective response rate with a 96% disease control rate in first-line G12D disease, and the same drug combined with gemcitabine and nab-paclitaxel hit 61% ORR. Those are the numbers that justify running RASolute 305, which is enrolling 670 patients. G12D is the single most common RAS mutation in pancreatic cancer, present in roughly 40% of patients, so a first-line win in that subset is not niche; it is the largest untapped slice of the disease. A confirmation of that magnitude at ASCO GI re-rates the first-line franchise, and a $43 billion cap leaves real room if first-line pancreatic becomes a second approved setting. Risk: first-line Phase 3 readouts are still months away, so the meeting may carry Phase 1/2 updates rather than a binary top line.

2. Summit Therapeutics (SMMT), $15.48, $12.35 billion cap. Ivonescimab is the PD-1/VEGF bispecific that has gone five for five in Phase 3, including the China-only HARMONi-GI1 win in biliary tract cancer (SMMT). The GI catalyst to screen is HARMONi-GI3, the global Phase 3 in first-line metastatic colorectal cancer testing ivonescimab plus mFOLFOX6 against bevacizumab plus mFOLFOX6. That trial only began enrolling in the fourth quarter of 2025, so a readout will not land by January. What ASCO GI could carry is detailed HARMONi-GI1 survival data and a HARMONi-GI3 enrollment update. The re-rate math is clean: a positive HARMONi-GI3 interim would extend the ivonescimab story beyond lung cancer into a tumor type with no PD-1/VEGF approval, and $12.35 billion still prices Summit mostly on the lung decision. Risk: the November 14 PDUFA in EGFR-mutant lung cancer resolves first and will set the stock’s baseline long before abstract day.

3. Zymeworks (ZYME), $27.12, $1.95 billion cap. The royalty play on zanidatamab, the HER2 bispecific that Jazz Pharmaceuticals sells as Ziihera. Zanidatamab is already approved in first-line HER2-positive gastroesophageal adenocarcinoma (GEA) and in second-line biliary tract cancer. Zymeworks holds the milestone and royalty stream, eligible for up to $1.3 billion in remaining milestones plus 10 to 20 percent royalties on Jazz’s sales. The screen at ASCO GI is the updated HERIZON-GEA-01 overall survival analysis, where the triplet arm already showed a median OS of 26.4 months versus 19.2 for trastuzumab plus chemo, a hazard ratio of 0.72 and a p-value of 0.0043. A matured OS analysis that holds that separation strengthens the standard-of-care case and the royalty trajectory. At a $1.95 billion cap, the royalty exposure is the entire story. Risk: ZYME moves as a fraction of any Jazz move, so the re-rate is real but capped relative to the drug’s commercial owner.

4. Arcus Biosciences (RCUS), $25.01, $3.18 billion cap. The pancreatic sleeper. Quemliclustat is a small-molecule CD73 inhibitor that blocks the immunosuppressive adenosine pathway, and it sits in PRISM-1, a registrational Phase 3 testing quemliclustat plus gemcitabine and nab-paclitaxel against chemo alone in untreated metastatic pancreatic cancer. Results are guided for the first half of 2027, which brackets ASCO GI and the ASCO Annual Meeting. The screen is a PRISM-1 top line or any updated ARC-8 biomarker data. A positive readout adds a second registrational oncology asset to a $3.18 billion company that the market currently values mostly on the casdatifan kidney cancer program. The re-rate math on a positive PRISM-1 is a genuine double, because pancreatic cancer has been a graveyard and a CD73 win would be a first-in-class. Risk: if PRISM-1 does not read out before the meeting, Arcus presents enrollment updates, not efficacy, and the binary moves to a later date.

5. Incyte (INCY), $124.82, $25.3 billion cap. The big-cap with two early GI shots. Incyte’s INCA33890, a TGFβR2 by PD-1 bispecific, posted a 15.2% objective response rate in microsatellite-stable colorectal cancer, a population where checkpoint monotherapy has been largely useless, and its INCB161734 is a KRAS G12D inhibitor in pancreatic cancer. The screen is updated Phase 1 data for either program. A differentiated MSS colorectal response rate or a compelling G12D pancreatic signal is exactly the kind of dataset that re-rates the GI segment of a company whose valuation rests on the broader oncology and inflammation franchise. Risk: these are Phase 1 data, and a $25 billion cap absorbs early reads more than a small cap would.

Mega-Cap Filter. Lilly’s olomorasib earned Breakthrough Therapy designation in KRAS G12C pancreatic cancer, but a $1.06 trillion market cap means the data moves zero basis points. AstraZeneca’s sonesitatug vedotin won overall survival in CLARITY-Gastric01 as the first CLDN18.2 ADC with a survival benefit in gastric cancer, but AstraZeneca’s $258 billion cap absorbs the readout; the tradable read-through is to smaller CLDN18.2 players like Innovent, whose arcotatug tavatecan is already under NMPA review, not to the AstraZeneca ticker. Merck’s Keytruda GI readouts are already reflected in a $367 billion cap. Exclude these from your screen list.

Catalyst-Consumed Caveat. Two names in this preview resolve before abstract day. Summit’s November 14 PDUFA in EGFR-mutant lung cancer is decided six weeks before full abstracts drop, and Revolution’s second-line daraxonrasib approval is already in the rear-view mirror. Neither is a January conference trade. Treat them as already priced, and screen the first-line and colorectal datasets instead.

The discipline is the same as the trading biotech conferences playbook: the trade fires at abstract release, not the podium. Full abstracts land January 19, 2027. Position 1 to 2 percent per binary event, and know that the January 19 gap is the move, not the January 21 session.

The verdict: screen RVMD and RCUS first. Both carry first-line pancreatic datasets that bracket ASCO GI 2027, and both are priced so that a positive read re-rates them 15 to 30 percent. Summit is the highest-conviction molecule but the lung decision, not the GI data, sets its price. Zymeworks is the royalty hedge with a real but capped move. Incyte is the big-cap lottery ticket. GI oncology’s first window of 2027 belongs to the first-line pancreatic names.

Sources: ASCO GI 2027 dates and abstract release, RASolute 303 first-line trial, HARMONi-GI3 colorectal trial.